ifenprodil has been researched along with Cancer of Liver in 1 studies
ifenprodil: NMDA receptor antagonist
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, F | 1 |
| Tong, M | 1 |
| Tong, CSW | 1 |
| Chan, BKC | 1 |
| Chu, HY | 1 |
| Wong, TL | 1 |
| Fong, JHC | 1 |
| Cheung, MSH | 1 |
| Mak, KH | 1 |
| Pardeshi, L | 1 |
| Huang, Y | 1 |
| Wong, KH | 1 |
| Choi, GCG | 1 |
| Ma, S | 1 |
| Wong, ASL | 1 |
1 other study available for ifenprodil and Cancer of Liver
| Article | Year |
|---|---|
A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, He | 2021 |